SCHEMBL3288144

SCHEMBL3288144

CCN(CC)C(=O)C1CCN(C(=O)OC)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 3/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 2/20 0.42
HPGD P15428 1/20 0.41
BCHE P06276 1/20 0.40
CHRM1 P11229 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
CHRM5 P08912 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2757989 0.81 GAA (0.42) GAAALDH1A1HPGDCHRM1SMN1; SMN2
SCHEMBL14590482 0.81 KDM4E (0.49) ALDH1A1KDM4EPKMHPGDBCHE
SCHEMBL12706377 0.79 KDM4E (0.48) ALDH1A1KDM4EPKMALOX15HPGD
SCHEMBL771883 0.78 GAA (0.41) GAACHRM1SMN1; SMN2MAPTMEN1
SCHEMBL2545481 0.77 KDM4E (0.51) ALDH1A1KDM4EPKMALOX15HPGD
SCHEMBL4347848 0.76 SMN1; SMN2 (0.46) GAAALDH1A1KDM4EPKMHPGD
SCHEMBL1289738 0.75 ALDH1A1 (0.47) ALDH1A1KDM4EPKMHPGDBCHE
SCHEMBL3497278 0.75 MAPT (0.66) GAAALDH1A1KDM4EMAPTL3MBTL1
SCHEMBL3498368 0.74 LMNA (0.55) GAASMN1; SMN2L3MBTL1LMNAKMT2A
SCHEMBL12436920 0.74 GAA (0.46) GAAALDH1A1HPGDCHRM1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304423-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICAL INCORPORATED (US) 2012-11-06 US disclosed
US-20120196857-A9 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-02 US disclosed
US-20120004226-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-05 US disclosed
US-8003660-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004226-A1 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 GAA 3044/4885ALDH1A1 2356/4885KDM4E 3396/4885
US-20120196857-A9 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 GAA 3044/4885ALDH1A1 2356/4885KDM4E 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.